Analysis of the migraine characteristics in the perimenopause

Characteristics of migraine in perimenopause have not been sufficiently analyzed.

Objective. To compare the course of migraine in patients of reproductive age (RA) and in perimenopause.

Material and methods. The observational cross-sectional study involved 120 women suffering from migraine: 60 in the RA group (mean age – 32.28 years), 60 in the perimenopause group (mean age – 48.13 years). Patients were interviewed and questionnaires were filled in, HIT-6, MIBS-4, HURT, Migraine ACT, MIDAS, SF-36, HADS and ISQ scales were used.

Results. The indicators of pain intensity, the duration of attacks and the number of days with headache per month are significantly higher in perimenopause than in RA (p<0.05). The risk of severe impact of headache on quality of life (HIT-6) and migraine burden outside of attacks (MIBS-4) are also significantly higher in perimenopause than in RA (OR=1.9 and OR=1.7, respectively; p><0.05), and most quality of life indicators (SF-36) are lower (p><0.05). The risk of arterial hypertension and musculoskeletal diseases is higher in perimenopause than in RA (OR=2.8 and OR=4.25, respectively; p><0.05). The risk of clinically pronounced anxiety and insomnia is higher in perimenopause than in RA (OR=2.4 and OR=5.15; p><0.05). Conclusion. The course of migraine in women in perimenopause is less favorable than in RA. Further studies are needed to determine the causes of the observed phenomena and to develop clinical guidelines for the treatment of perimenopausal migraine patients.><0.05) The risk of severe impact of headache on quality of life (HIT-6) and migraine burden outside of attacks (MIBS-4) are also significantly higher in perimenopause than in RA (OR=1.9 and OR=1.7, respectively; p<0.05), and most quality of life indicators (SF-36) are lower (p><0.05). The risk of arterial hypertension and musculoskeletal diseases is higher in perimenopause than in RA (OR=2.8 and OR=4.25, respectively; p><0.05). The risk of clinically pronounced anxiety and insomnia is higher in perimenopause than in RA (OR=2.4 and OR=5.15; p><0.05). Conclusion. The course of migraine in women in perimenopause is less favorable than in RA. Further studies are needed to determine the causes of the observed phenomena and to develop clinical guidelines for the treatment of perimenopausal migraine patients.><0.05) ), and most quality of life indicators (SF-36) are lower (p<0.05). The risk of arterial hypertension and musculoskeletal diseases is higher in perimenopause than in RA (OR=2.8 and OR=4.25, respectively; p><0.05). The risk of clinically pronounced anxiety and insomnia is higher in perimenopause than in RA (OR=2.4 and OR=5.15; p><0.05). Conclusion. The course of migraine in women in perimenopause is less favorable than in RA. Further studies are needed to determine the causes of the observed phenomena and to develop clinical guidelines for the treatment of perimenopausal migraine patients.><0.05). The risk of arterial hypertension and musculoskeletal diseases is higher in perimenopause than in RA (OR=2.8 and OR=4.25, respectively; p<0.05). The risk of clinically pronounced anxiety and insomnia is higher in perimenopause than in RA (OR=2.4 and OR=5.15; p<0.05)

Conclusion. The course of migraine in women in perimenopause is less favorable than in RA. Further studies are needed to determine the causes of the observed phenomena and to develop clinical guidelines for the treatment of perimenopausal migraine patients.

1. Russian Society of Obstetricians and Gynecologists. Menopause and climacteric conditions in women. Clinical guidelines. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/117_2 (In Russ.).

2. Yureneva SV, Ilyina LM, Smetnik VP. Aging of the female reproductive system: from theory to clinical practice. Part I. Endocrine and clinical characteristics of the stages of female reproductive aging. Akusherstvo i ginekologiya. 2014;(3):21-7 (In Russ.).

3. Wang SJ, Fuh JL, Lu SR, et al. Migraine prevalence during menopausal transition. Headache. 2003 May;43(5):470-8. doi: 10.1046/j.1526-4610.2003.03092.x

4. Ripa P, Ornello R, Degan D, et al. Migraine in menopausal women: a systematic review. Int J Womens Health. 2015 Aug 20;7:773-82. doi: 10.2147/IJWH.S70073

5. MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reprod Health. 2018 Mar;24(1):11-8. doi: 10.1177/2053369117731172. Epub 2017 Oct 10.

6. Oh K, Jung KY, Choi JY, et al. Headaches in middle-aged women during menopausal transition: a headache clinic-based study. Eur Neurol. 2012;68(2):79-83. doi: 10.1159/000336838. Epub 2012 Jul 3.

7. Martin VT, Pavlovic J, Fanning KM, et al. Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. Headache. 2016 Feb;56(2):292-305. doi: 10.1111/head.12763. Epub 2016 Jan 21.

8. Maleki N, Cheng YC, Tu Y, Locascio JJ. Longitudinal course of vasomotor symptoms in perimenopausal migraineurs. Ann Neurol. 2019 Jun;85(6):865-74. doi: 10.1002/ana.25476. Epub 2019 Apr 30.

9. Alebna P, Maleki N. Allostatic Load in Perimenopausal Women With Migraine. Front Neurol. 2021 Apr 22;12:649423. doi: 10.3389/fneur.2021.649423

10. Gao Y, Tang R, Li J, et al. Generalized headache among Chinese climacteric women: findings from a prospective cohort. Climacteric. 2021 Jun;24(3):289-96. doi: 10.1080/13697137.2021.1881058. Epub 2021 Feb 17.

11. Cupini LM, Matteis M, Troisi E, et al. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995 Apr;15(2):140-4. doi: 10.1046/j.1468-2982.1995.015002140.x

12. MacGregor EA. Menstrual and perimenopausal migraine: A narrative review. Maturitas. 2020 Dec;142:24-30. doi: 10.1016/j.maturitas.2020.07.005. Epub 2020 Jul 10.

13. Lagman-Bartolome AM, Lay C. Migraine in Women. Neurol Clin. 2019 Nov;37(4):835-45. doi: 10.1016/j.ncl.2019.07.002. Epub 2019 Aug 22.

14. Karpova MI, Zariada AA, Dolgushina VF, et al. Migraine in women: clinical and therapeutical aspects. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3):98- 107. doi: 10.17116/jnevro201911903198 (In Russ.).

15. Hipolito Rodrigues MA, Maitrot-Mantelet L, Plu-Bureau G, Gompel A. Migraine, hormones and the menopausal transition. Climacteric. 2018 Jun;21(3):256-66. doi: 10.1080/13697137.2018.1439914. Epub 2018 Mar 9.

16. Faubion SS, Batur P, Calhoun AH. Migraine Throughout the Female Reproductive Life Cycle. Mayo Clin Proc. 2018 May;93(5):639-45. doi: 10.1016/j.mayocp.2017.11.027

17. Maksyukova EV, Osipova VV. Migraine in older patients: clinical and psychological analysis. Rossiyskiy zhurnal boli. 2011;(2):33 (In Russ.).

18. Wang Z, VanderPluym JH, Halker Singh RB, et al. Safety of Triptans in Patients Who Have or Are at High Risk for Cardiovascular Disease: A Target Trial Emulation. Mayo Clin Proc. 2024 Nov;99(11):1722-31. doi: 10.1016/j.mayocp.2024.03.023. Epub 2024 Aug 30.

19. Sharma P, Varghese Gupta S, Bhatt P, et al. Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS). Can J Physiol Pharmacol. 2024 Oct 22. doi: 10.1139/cjpp2024-0117. Epub ahead of print.

20. Petersen CL, Hougaard A, Gaist D, Hallas J. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans. JAMA Neurol. 2024 Mar 1;81(3):248-54. doi: 10.1001/jamaneurol.2023.5549

21. Tabeeva GR, Amelin AV, Akhmadeeva LR, et al. Optimization of migraine attacks relief. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):126-33. doi: 10.14412/2074-2711-2023-2-126-133 (In Russ.).

22. Tabeeva GR, Danilov AB, Koreshkina MI, et al. Experience of using Russian rizatriptan 10 mg tablets in routine clinical practice: results of a multicenter post-registration observational study “OPYT”. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(5):60-8. doi: 10.14412/2074-2711-2024-5-60-68 (In Russ.).

23. Bech-Drewes A, Bonnesen K, Hauge EM, Schmidt M. Cardiovascular safety of using nonsteroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study. Rheumatol Int. 2024 Jun;44(6):1061-9. doi: 10.1007/s00296-024-05584-7. Epub 2024 Apr 6.

24. Clinard F, Sgro C, Bardou M, et al. Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. Eur J Clin Pharmacol. 2004 Jun;60(4):279-83. doi: 10.1007/s00228-004-0761-0. Epub 2004 Apr 22.

25. Szkutnik-Fiedler D. Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine DrugsLasmiditan, Gepants, and Calcitonin-GeneRelated Peptide (CGRP) Receptor Monoclonal Antibodies. Pharmaceutics. 2020 Dec 3;12(12):1180. doi: 10.3390/pharmaceutics12121180

26. Laohapiboolrattana W, Jansem P, Anukoolwittaya P, et al. Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis. J Headache Pain. 2024 Nov 8;25(1):194. doi: 10.1186/s10194-024-01904-1

27. Rissardo JP, Caprara ALF. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review. Brain Sci. 2022 Nov 24;12(12):1612. doi: 10.3390/brainsci12121612

28. Guziy EA, Sergeev AV, Tabeeva GR. Evaluation of the efficacy of preventive therapy in chronic migraine with or without medication overuse headache: data from a prospective study. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1S):59-65. doi: 10.14412/2074-2711-2024-1S-59-65 (In Russ.).

29. Chhabra N, Mead-Harvey C, Dodoo CA, et al. Blood pressure elevation in erenumabtreated patients with migraine: A retrospective real-world experience. Headache. 2024 Mar;64(3):233-42. doi: 10.1111/head.14679. Epub 2024 Feb 27.

30. Wang K, Fenton BT, Dao VX, et al. Trajectory of blood pressure after initiating anticalcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration. J Headache Pain. 2023 Aug 15;24(1):108. doi: 10.1186/s10194-023-01640-y

31. Azimova YuE, Amelin AV, Alferova VV, et al. Clinical guidelines “Migraine”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134 (In Russ.).

32. Sergeev AV, Tabeeva GR, Filatova EG, et al. Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116 (In Russ.).

33. Luo J. Association between migraine and anxiety symptoms: Results from the study of women's health across the nation. J Affect Disord. 2021 Dec 1;295:1229-33. doi: 10.1016/j.jad.2021.09.036. Epub 2021 Sep 17.

34. McCracken HT, Thaxter LY, Smitherman TA. Psychiatric comorbidities of migraine. Handb Clin Neurol. 2024;199:505-16. doi: 10.1016/B978-0-12-823357-3.00013-6

35. Lyndon GJ, Prieto R, Wajsbrot DB, et al. Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity. Int Clin Psychopharmacol. 2019 May;34(3):110-8. doi: 10.1097/YIC.0000000000000256

36. Guaiana G, Meader N, Barbui C, et al. Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database Syst Rev. 2023 Nov 28;11(11):CD012729. doi: 10.1002/14651858.CD012729.pub3

37. Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. Obstet Gynecol Clin North Am. 2011 Sep;38(3):567-86. doi: 10.1016/j.ogc.2011.06.002

38. Schaedel Z, Holloway D, Bruce D, Rymer J. Management of sleep disorders in the menopausal transition. Post Reprod Health. 2021 Dec;27(4):209-14. doi: 10.1177/20533691211039151. Epub 2021 Nov 8.

39. Bakker MH, Hugtenburg JG, Smits MG, et al. Off-label low dose amitriptyline for insomnia disorder: Patient-reported outcomes. Pharmacoepidemiol Drug Saf. 2023 Apr;32(4):435-45. doi: 10.1002/pds.5561. Epub 2022 Nov 20.

40. Faubion SS, Smith T, Thielen J, et al. Association of Migraine and Vasomotor Symptoms. Mayo Clin Proc. 2023 May;98(5):701-12. doi: 10.1016/j.mayocp.2023.01.010

41. Nappi RE, Cagnacci A, Granella F, et al. Course of primary headaches during hormone replacement therapy. Maturitas. 2001 Apr 20;38(2):157-63. doi: 10.1016/s0378-5122(00)00215-2

42. Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women. Headache. 2002 Oct;42(9):924-9. doi: 10.1046/j.1526-4610.2002.02215.x. Erratum in: Headache. 2003 Feb;43(2):172. Erratum in: Headache. 2003 Mar;43(3):310.

43. Misakian AL, Langer RD, Bensenor IM, et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt). 2003 Dec;12(10):1027-36. doi: 10.1089/154099903322643956

44. Aegidius KL, Zwart JA, Hagen K, et al. Hormone replacement therapy and headache prevalence in postmenopausal women. The HeadHUNT study. Eur J Neurol. 2007 Jan;14(1):73- 8. doi: 10.1111/j.1468-1331.2006.01557.x

45. Kim S, Lee SB, Hong YJ, et al. The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea. Cephalalgia. 2022 Apr;42(4-5):376-84. doi: 10.1177/03331024211044441. Epub 2021 Sep 27.

46. Witten T, Staszkiewicz J, Gold L, et al. Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms. Cureus. 2024 Jan 17;16(1):e52467. doi: 10.7759/cureus.52467

47. Schaudig K, Wang X, Bouchard C, et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ. 2024 Nov 18;387:e079525. doi: 10.1136/bmj-2024-079525.